by Elena Iemma | Oct 24, 2024 | News
PROVIDENCE, R.I., Oct. 24, 2024 /PRNewswire/ — EpiVax, Inc. and CUBRC, Inc. announce today that they have been awarded a two-year, $2 million contract (#75F40124C00094) from the Office of Generic Drugs (OGD) of the Food and Drug...
by Elena Iemma | Aug 18, 2024 | Blog
Immunogenicity Risk Assessment: In Silico, In Vitro, and What’s Next Don’t Miss This one! Put this one on your calendar: Scientific and Regulatory Considerations for Assessment of Immunogenicity Risk … The gang will all be...
by Elena Iemma | Jul 22, 2022 | Events
A big thank you to everyone that came out to the pre-conference Computational Vaccinology workshop at ISV! Agenda and pictures from the day below. ISV 2022 Computational Vaccinology Conference Workshop Saturday September 17, 9-4 pm ET Delta Hotels Québec 690 Boul René...
by Elena Iemma | Mar 11, 2021 | Events, Webinars
Aimee Mattei, Senior Project Manager on our Bioinformatics team, will be presenting to the AAPS BPABC(biopharmaceutical product attributes and biological consequences) Community on March 18th at 12pm ET. You’ll need to join the group to register, membership is...
by Elena Iemma | Jan 26, 2021 | Events, Webinars
The FDA hosted a virtual workshop January 26, 2021 to provide updates and foster discussions around non-clinical assays for comparative immunogenicity risk assessment of generic peptide products. EpiVax CEO/CSO, Annie De Groot, presented an update on EpiVax’s...
